Mostrando 2 resultados de: 2
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
ArticleAbstract: Background: Cushing's disease is a rare endocrine disorder characterised by cortisol overproductionPalabras claves:Autores:Bertagna X., Biller B.M.K., Findling J.W., Fleseriu M., Gu F., Kim J.H., Lacroix A., Laplanche A., Lee E.J., Leelawattana R., Newell-Price J., O'Connell P., Pedroncelli A.M., Pivonello R., Richard J. Auchus, Shimatsu A., Tauchmanova L.Fuentes:scopusLong-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
ArticleAbstract: Objective: To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11βPalabras claves:Autores:Belaya Z., Biller B.M.K., Feelders R.A., Fleseriu M., Houde G., Izquierdo M., Newell-Price J., Pedroncelli A.M., Pivonello R., Richard J. Auchus, Roughton M., Scaroni C., Shimatsu A., Vila G., Walia R.Fuentes:scopus